Enter drug's generic or brand name below. Results will appear here. Note: all drug related information obtained on this page is provided by RX List.
Using the RX LIST database:
(1) Enter the drug name in the search box below and hit ENTER
(2) The rx list web site will open here with the drug search completed. Next, scroll down the page to locate the link to the drug you are searching for and then click on the link.
INFUVITE PEDIATRIC
(multiple vitamins) Injection
INFUVITE PEDIATRIC (multiple vitamins injection) is a sterile product consisting of 2 vials provided as a pharmacy bulk package for intravenous use:
A pharmacy bulk package is a container of a sterile preparation for parenteral use that contains many single doses. The contents are intended for use in a pharmacy admixture program and are restricted to the preparation of admixtures for intravenous infusion [see DOSAGE AND ADMINISTRATION].
Each 4 mL of Vial 1 contains 10 vitamins (see Table 2).
Table 2: Active Ingredients in 4 mL of Vial 1
| Active Ingredient | Quantity |
| Ascorbic acid (Vitamin C) | 80 mg |
| Vitamin A* (as palmitate) | 2,300 IU (equals 0.7 mg) |
| Vitamin D3* (cholecalciferol) | 400 IU (equals 10 mcg) |
| Thiamine (Vitamin B1) (as the hydrochloride) | 1.2 mg |
| Riboflavin (Vitamin B2) (as riboflavin 5-phosphate sodium) | 1.4 mg |
| Pyridoxine HCl (Vitamin B6) | 1 mg |
| Niacinamide | 17 mg |
| Dexpanthenol (as d-pantothenyl alcohol) | 5mg |
| Vitamin E* (dl-α-tocopheryl acetate) | 7 IU (equals 7 mg) |
| Vitamin K1* | 0.2 mg |
| *Polysorbate 80 is used to water solubilize the oil-soluble vitamins A, D, E, and K. | |
Inactive ingredients in Vial 1: 50 mg polysorbate 80, sodium hydroxide and/or hydrochloric acid for pH adjustment, and water for injection. Each 1 mL of Vial 2 contains 3 vitamins (see Table 3).
Table 3: Active Ingredients
in 1 mL of Vial 2
| Active Ingredient | Quantity |
| Folic acid | 140 mcg |
| Biotin | 20 mcg |
| Vitamin B12 (cyanocobalamin) | 1 mcg |
Inactive ingredients in Vial 2: 75 mg mannitol, citric acid and/or sodium citrate for pH adjustment and water for injection.
INFUVITE PEDIATRIC (multiple vitamins injection) makes available a combination of oil-soluble and water-soluble vitamins in an aqueous solution, formulated for incorporation into intravenous solutions. The liposoluble vitamins A, D, E, and K have been solubilized in an aqueous medium with polysorbate 80, permitting intravenous administration of these vitamins.
INFUVITE PEDIATRIC contains no more than 30 mcg/L of aluminum (combined Vials 1 and 2).
INFUVITE PEDIATRIC is a combination of vitamins indicated for the prevention of vitamin deficiency in pediatric patients up to 11 years of age receiving parenteral nutrition.
The physician should not await the development of clinical signs of vitamin deficiency before initiating vitamin therapy.
INFUVITE PEDIATRIC is a combination product that contains the following vitamins: ascorbic acid, vitamin A, vitamin D, thiamine, riboflavin, pyridoxine, niacinamide, dexpanthenol, vitamin E, vitamin K1, folic acid, biotin, and vitamin B12 [see Dosage Information].
INFUVITE PEDIATRIC is supplied as a pharmacy bulk package, and consists of two pharmacy bulk vials which must be combined and diluted prior to intravenous administration [see Preparation And Administration Instructions]. As a pharmacy bulk vial, INFUVITE PEDIATRIC is intended for dispensing of single doses to many patients in a pharmacy admixture program and is restricted to the preparation of admixtures for infusion. Each closure shall be penetrated only one time with a suitable sterile transfer device or dispensing set that allows measured dispensing of the contents. INFUVITE PEDIATRIC is to be used only in a suitable work area such as a laminar flow hood (or an equivalent clean air compounding area).
Dispensing from a pharmacy bulk vial should be completed within 4 hours after the vial is penetrated. After combining contents of the two vials, a specified volume of INFUVITE PEDIATRIC is added to intravenous fluids prior to intravenous administration [see Preparation And Administration Instructions]. Do not administer INFUVITE PEDIATRIC as a direct, undiluted intravenous injection as it may cause dizziness, faintness, and possible tissue irritation.
The recommended daily dosage volume of 1.5 mL, 3.25 mL, or 5 mL of the combined contents of Vials 1 and 2 is based on the patient's actual weight of less than 1 kg, 1 kg to less than 3 kg, and more than or equal to 3 kg, respectively (see Table 1). One daily dose of combined content of vials 1 and 2 (1.5 mL, 3.25 mL or 5 mL) is then added directly to the intravenous fluid [see Preparation And Administration Instructions]. Patients with multiple vitamin deficiencies or with increased vitamin requirements may need multiple daily dosages as indicated or additional doses of individual vitamins. However, additional daily dosages in infants are not recommended [see WARNINGS AND PRECAUTIONS]. Supplemental vitamin A may be required for low-birth weight infants.
Table 1: Recommended Weight-Based Dosage of INFUVITE
PEDIATRIC
| Less than 1 kg | ≥ 1 kg and < 3 kg | More than or equal to 3 kg | |
| Daily Dosage Volume | 1.5 mL | 3.25 mL | 5 mL |
| Ascorbic acid (Vitamin C) | 24 mg | 52 mg | 80 mg |
| Vitamin A (as palmitate) | 690 IU (equals 0.2 mg) | 1495 IU (equals 0.5 mg) | 2,300 IU (equals 0.7 mg) |
| Vitamin D3 (cholecalciferol) | 120 IU (equals 3 mcg) | 260 IU (equals 7 mcg) | 400 IU (equals 10 mcg) |
| Thiamine (Vitamin B1) (as the hydrochloride) | 0.4 mg | 0.8 mg | 12 mg |
| Riboflavin (Vitamin B2) (as riboflavin 5-phosphate sodium) | 0.4 mg | 0.9 mg | 1.4 mg |
| Pyridoxine HCl (Vitamin B6) | 0.3 mg | 0.7 mg | 1 mg |
| Niacinamide | 5.1 mg | 11.1 mg | 17 mg |
| Dexpanthenol (as J-pantothenyl alcohol) | 15 mg | 3.3 mg | 5 mg |
| Vitamin E (dl-a-tocopheryl acetate) | 2.1 IU (equals 2 mg) | 4.6 IU (equals 5 mg) | 7 IU (equals 7 mg) |
| Vitamin K1 | 0.1 mg | 0.1 mg | 0.2 mg |
| Folic acid | 42 mcg | 91 mcg | 140 mcg |
| Biotin | 6 mcg | 13 mcg | 20 mcg |
| Vitamin B12 (cyanocobalamin) | 0.3 mcg | 0.7 mcg | 1 mcg |
INFUVITE PEDIATRIC is supplied as a pharmacy bulk package. It consists of two pharmacy bulk vials that must be combined and diluted prior to intravenous administration.
Blood vitamin concentrations should be monitored to ensure maintenance of adequate levels, particularly in patients receiving parenteral multivitamins as the only credit of vitamins for long periods of time.
INFUVITE PEDIATRIC is an injection consisting of two vials labeled Vial 1 (40 mL Fill in 50 mL Vial) and Vial 2 (10 mL). The mixed solution (50 mL) will provide thirty-three 1.5 mL single doses, fifteen 3.25 mL single doses or ten 5 mL single doses. For the vitamin strengths, see Dosage Information and DESCRIPTION.
INFUVITE PEDIATRIC (multiple vitamins injection) is supplied as a pharmacy bulk package available in boxes containing 2 vials – Vial 1 (40 mL Fill in 50 mL Vial) and Vial 2 (10 mL). Mix contents of Vial 2 with Vial 1 to provide thirty-three 1.5 mL single doses, fifteen 3.25 mL single doses or 10 single 5 mL doses [see Dosage Information and Preparation And Administration Instructions].
NDC 54643-5647-0 Store at 2-8°C (36-46°F).
Manufactured by: Sandoz Canada Inc., 145 Jules-Léger Street Boucherville, Qc, Canada, J4B 7K8. Distributed by: Baxter Healthcare Corporation, Clintec Nutrition Division Deerfield, IL 60015 USA, Revised: Jul 2014
The following adverse reactions are discussed in greater detail in other sections of the labeling.
The following adverse reactions have been identified during postapproval use of the vitamins in INFUVITE PEDIATRIC. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Dermatologic: rash, erythema, pruritis
CNS: headache, dizziness, agitation, anxiety
Ophthalmic: diplopia
A number of interactions between vitamins and drugs have been reported. The following are examples of these types of interactions:
Warfarin: Vitamin K, a component of INFUVITE PEDIATRIC, antagonizes the anticoagulant action of warfarin. In patients who are co-administered warfarin and INFUVITE PEDIATRIC, blood levels of prothrombin/INR should be periodically monitored to determine if dose of warfarin needs to be adjusted.
Antibiotics: Thiamine, riboflavin, pyridoxine, niacinamide, and ascorbic acid decrease antibiotic activities of erythromycin, kanamycin, streptomycin, doxycycline, and lincomycin.
Bleomycin: Ascorbic acid and riboflavin inactivate bleomycin in vitro, thus the activity of bleomycin may be reduced.
Levodopa: Pyridoxine may increase the metabolism of levodopa (decrease blood levels of levodopa) and decrease its  efficacy.
Phenytoin: Folic acid may increase phenytoin metabolism and lower the serum concentration of phenytoin resulting in increased seizure activity.
Methotrexate: Folic acid may decrease a patient's response to methotrexate therapy.
Hydralazine, Isoniazid:
Concomitant administration of hydralazine or isoniazid may increase pyridoxine requirements.
Phenytoin:
Phenytoin may decrease serum folic acid concentrations.
Included as part of the PRECAUTIONS section.
INFUVITE PEDIATRIC contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration in pediatric patients with renal impairment. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solution, which contain aluminum.
Patients with renal impairment, including premature neonates who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration. Consider periodic monitoring of aluminum levels with prolonged parenteral administration of INFUVITE PEDIATRIC.
Allergic reactions such as urticaria, shortness of breath, wheezing and angioedema have been reported following intravenous administration of thiamine, which is found in INFUVITE PEDIATRIC. There have been rare reports of anaphylaxis following intravenous doses of thiamine. No fatal anaphylaxis associated with INFUVITE PEDIATRIC has been reported.
Hypervitaminosis A, manifested by nausea, vomiting, headache, dizziness, blurred vision has been reported in patients with renal failure receiving 1.5 mg/day retinol and in patients with liver disease. Therefore, supplementation of renal failure patients and patients with liver disease with vitamin A, an ingredient found in INFUVITE PEDIATRIC, should be undertaken with caution [See Use in Specific Populations]. Blood levels of Vitamin A should be monitored periodically.
Vitamin K, which is found in INFUVITE PEDIATRIC, antagonizes the anticoagulant action of warfarin. In patients who are on warfarin anticoagulant therapy receiving parenteral multivitamins such as with INFUVITE PEDIATRIC blood levels of prothrombin/INR should be periodically monitored to determine if dose of warfarin needs to be adjusted.
Avoid the use of INFUVITE PEDIATRIC in patients with suspected or diagnosed megaloblastic anemia prior to blood sampling for the detection of the folic acid and cyanocobalamin deficiencies. The folic acid and the cyanocobalamin in INFUVITE PEDIATRIC can mask serum deficits of folic acid and cyanocobalamin in these patients.
In patients receiving parenteral multivitamins such as with INFUVITE PEDIATRIC, blood concentration should be periodically monitored to determine if vitamin deficiencies or excesses are developing. INFUVITE PEDIATRIC may not correct long-standing specific vitamin deficiencies. The administration of additional doses of specific vitamins may be required [see DOSAGE AND ADMINISTRATION].
INFUVITE PEDIATRIC contains vitamin C which is also known as ascorbic acid. Ascorbic acid in the urine may cause false negative urine glucose determinations.
Avoid additional oral or parental doses of vitamin E in infants. Daily dose of INFUVITE PEDIATRIC contains adequate concentrations of vitamin E required to achieve normal blood levels of vitamin E. Therefore, additional vitamin E supplementations of patients receiving INFUVITE PEDIATRIC may result in elevated blood concentrations of vitamin E and potential vitamin E toxicity in infants.
Vitamin A may adhere to plastic, resulting in lower vitamin A concentrations after administration of INFUVITE PEDIATRIC. Therefore, blood vitamin concentrations should be periodically monitored and the administration of additional therapeutic doses of vitamin A may be required, especially in low-birth weight infants.
E-Ferol syndrome manifested by thrombocytopenia, renal dysfunction, hepatomegaly, cholestasis, ascites, hypotension and metabolic acidosis has been reported in low-birth weight infants following administration of polysorbates which are found in INFUVITE PEDIATRIC. No E-Ferol syndrome associated with INFUVITE PEDIATRIC has been reported.
Carcinogenicity, mutagenicity, and fertility studies have not been performed with INFUVITE PEDIATRIC.
Pregnancy Category C.
INFUVITE PEDIATRIC has not been studied in pregnant women. Pregnant women should follow the U.S. recommended daily allowances for pregnancy because their vitamin requirements may exceed those of non-pregnant women. Animal reproduction studies have not been conducted with INFUVITE PEDIATRIC (multiple vitamins injection).
INFUVITE PEDIATRIC has not been studied in nursing mothers. Lactating women may have vitamin requirements that exceed those of non-lactating women. Caution should be exercised when INFUVITE PEDIATRIC is administered to nursing mothers.
INFUVITE PEDIATRIC is approved for the prevention of vitamin deficiency in pediatric patients up to 11 years old receiving parenteral nutrition. INFUVITE PEDIATRIC has not been studied in pediatric patients older than 11 years.
INFUVITE PEDIATRIC contains aluminum that may be toxic for premature neonates. Aluminum levels should be monitored periodically during administration of INFUVITE PEDIATRIC to premature neonates [see WARNINGS AND PRECAUTIONS].
Additional vitamin E supplementations of infants receiving INFUVITE PEDIATRIC may result in elevated blood concentrations of vitamin E and potential vitamin E toxicity [see WARNINGS AND PRECAUTIONS].
E-Ferol syndrome has been reported in low-birth weight infants following administration of polysorbates which are found in INFUVITE PEDIATRIC. No E-Ferol syndrome associated with INFUVITE PEDIATRIC has been reported [see WARNINGS AND PRECAUTIONS].
INFUVITE PEDIATRIC has not been studied in patients with renal impairment. Monitor renal function, calcium, phosphorus and vitamin A levels in patients with renal impairment [see WARNINGS AND PRECAUTIONS].
INFUVITE PEDIATRIC has not been studied in patients with liver impairments. Monitor vitamin A levels in patients with liver disease [see WARNINGS AND PRECAUTIONS].
Signs and symptoms of acute or chronic overdosage may be those of individual INFUVITE PEDIATRIC component toxicity. There is no clinical experience with INFUVITE PEDIATRIC overdosage.
INFUVITE PEDIATRIC is contraindicated in patients who have:
No information provided.
Instruct caregiver(s) and patients (if age appropriate) that:
